Relationship between antipsychotics and weight in patients with prader-willi syndrome

Pharmacotherapy

Volumn 35, Issue 3, 2015, Pages 260-268

  Elliott, Jennifer Padden ^a   Cherpes, Gregory ^b   Kamal, Khalid ^a   Chopra, Ishveen ^a   Harrison, Chelsea ^a   Riedy, Mary ^a   Herk, Brandon ^a   McCrossin, Matt ^a   Kalarchian, Melissa ^a  

^a DUQUESNE UNIVERSITY   (United States)

^b Children's Institute of Pittsburgh   (United States)

Author keywords

antipsychotics; drug safety; obesity

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TIOTIXENE; ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG USE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRADER WILLI SYNDROME; PRESCRIPTION; RETROSPECTIVE STUDY; WEIGHT REDUCTION; BODY WEIGHT; DRUG EFFECTS; PRADER-WILLI SYNDROME; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; MALE; PRADER-WILLI SYNDROME; RETROSPECTIVE STUDIES; WEIGHT LOSS; YOUNG ADULT;

EID: 84925408793     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1558     Document Type: Article

References (50)

1. Prader A, Labhart A, Willi A,. Ein syndrom von aidositas, kleinwuchs, kryptorchismus und oligophrenie nach myotonieartigem zustand im neugeborenenalter. Schweiz Med Wochenschr 1956; 86: 1260-1.
2. Butler MG, Meaney FJ, Palmer CG,. Clinical and cytogenetic survey of 39 individuals with Prader-Labhart-Willi syndrome. Am J Med Genet 1986; 23: 793-809.
3. Whittington JE, Holland AJ, Webb T, et al. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001; 38: 792-8.
4. Butler MG, Thompson T,. Prader-Willi syndrome: clinical and genetic findings. Endocrinologist 2000; 10: 3S-16S.
5. Nicholls RD, Knepper JL,. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet 2001; 2: 153-75.
6. Cassidy S, Driscoll D,. Prader-Willi syndrome. Eur J Hum Genet 2009; 17: 3-13.
7. Schrander-Stumpel CT, Curfs LM, Sastrowijto P, Cassidy SB, Schrander JJ, Fryns JP,. Prader-Willi syndrome: causes of death in an international series of 27 cases. Am J Med Genet A 2004; 124: 333-8.
8. Stevenson DA, Anaya TM, Clayton-Smith J, et al. Unexpected death and critical illness in Prader-Willi syndrome: report of ten individuals. Am J Med Genet A 2004; 124A: 158-64.
9. Einfeld SL, Kavanagh SJ, Smith A, Evans EJ, Tonge BJ, Taffe J,. Mortality in Prader-Willi syndrome. Am J Ment Retard 2006; 111: 193-8.
10. Grugni G, Crino A, Bosio L, et al. The Italian National Survey for Prader-Willi syndrome: an epidemiologic study. Am J Med Genet 2008; 146: 861-72.
11. Brambilla P, Crino A, Bedogni G, et al. Metabolic syndrome in children with Prader-Willi syndrome: the effect of obesity. Nutr Metab Cardiovasc Dis 2011; 21: 269-76.
12. Dykens EM, Hodapp RM, Walsh KK, et al. Profiles, correlates, and trajectories of intelligence in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1992; 31: 1125-30.
13. Dykens EM, Cassidy SB,. Correlates of maladaptive behavior in children and adults with Prader-Willi syndrome. Am J Med Genet 1995; 60: 546-9.
14. Dykens E, Shah B,. Psychiatric disorders in Prader-Willi Syndrome. CNS Drugs 2003; 7: 167-78.
15. Dykens EM, Cassidy SB, King BH,. Maladaptive behavior differences in Prader-Willi syndrome due to paternal deletion versus maternal uniparental disomy. Am J Ment Retard 1999; 104: 67-77.
16. Beardsmore A, Dorman T, Cooper SA, et al. Affective psychosis and Prader-Willi syndrome. J Intellect Disabil Res 1998; 42: 463-71.
17. Clarke DJ, Boer H, Webb T, et al. Prader-Willi syndrome and psychotic symptoms: case descriptions and genetic studies. J Intellect Disabil Res 1998; 42: 440-50.
18. Clarke DJ,. Prader-Willi syndrome and psychoses. Br J Psychiatry 1993; 163: 680-4.
19. Clarke DJ, Webb T, Bachmann-Clarke JP,. Prader-Willi syndrome and psychotic symptoms: report of a further case. Ir J Psychol Med 1995; 12: 27-9.
20. Roof E, Stone W, MacLean W, Feurer ID, Thompson T, Butler MG,. Intellectual characteristics of Prader-Willi syndrome: comparison of genetic subtypes. J Intellect Disabil Res 2000; 44: 25-30.
21. Mitchell J, Schinzel A, Langlois S, et al. Comparison of phenotype in uniparental disomy and deletion Prader-Willi syndrome: sex differences. Am J Med Genet 1996; 65: 133-6.
22. Dykens EM,. Are jigsaw puzzle skills "spared" in persons with Prader-Willi syndrome? J Child Psychol Psychiatry 2002; 43: 343-52.
23. Cassidy SB, Forsythe M, Heeger S, et al. Comparison of phenotype between patients with Prader-Willi syndrome due to deletion 15q and uniparental disomy 15. Am J Med Genet 1997; 68: 433-40.
24. Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T,. Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics 2004; 113: 565-73.
25. Torrado M, Araoz V, Baialardo E, et al. Clinical-etiologic correlation in children with Prader-Willi syndrome (PWS): an intradisciplinary study. Am J Med Genet 2007; 143A: 460-8.
26. Vogels A, De Her M, Descheemaeker MJ, et al. Psychotic disorders in Prader-Willi syndrome. Am J Med Genet 2004; 127A: 238-43.
27. Zarcone J, Napolitano D, Peterson C, et al. The relationship between compulsive behaviour and academic achievement across the three genetic subtypes of Prader-Willi syndrome. J Intellect Disabil Res 2007; 51: 478-87.
28. Holsen LM, Zarcone JR, Chambers R, et al. Genetic subtype differences in neural circuitry of food motivation in Prader-Willi syndrome. Int J Obes 2009; 33: 273-83.
29. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306: 1359-70.
30. Aquila R, Emanuel M,. Interventions for weight gain in adults treated with novel antipsychotics. J Clin Psychiatry 2000; 2: 20-3.
31. Khan R, Mican L, Suehs B,. Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation. J Psychiatr Pract 2009; 15: 321-8.
32. McIntyre RS, Mancini DA, Basile VS,. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001; 62: 23-9.
33. Rege S,. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008; 42: 369-81.
34. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-63.
35. Osser DN, Najarian DM, Dufrense RL,. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767-70.
36. Pollmacher T, Hinze-Selch D, Mullington J,. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16: 403-9.
37. Cabrera R, Mayor P, Fernandez-Ruiz J, et al. Insulin binding and action on adipocytes from female rats with experimentally induced chronic hyperprolactinemia. Mol Cell Endocrinol 1988; 58: 167-73.
38. Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999; 9: 239-45.
39. Sikick L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA,. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29: 133-45.
40. Sikick L, Frazier JA, McClellan RL, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165: 1420-31.
41. Maayan L, Correll C,. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011; 21: 517-35.
42. Kane J, Correll C,. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71: 1115-24.
43. Weterling T,. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2000; 24: 59-73.
44. Kinon BJ, Basson MS, Gilmore LM,. Long term olanzapine treatment, weight change and weigh-related health factors in schizophrenia. J Clin Psychiatry 2001; 62 (2): 92-100.
45. Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J,. Risperidone in treating behavioral disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 2000; 102: 461-5.
46. Araki S, Ohji T, Shiota N, Dobashi K, Shimono M, Shirahata A,. Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatr Int 2010; 52: e1-3.
47. Miller JL, Lynn CH, Driscoll DC, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A 2011; 155A: 1040-9.
48. Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2011; 21: 621-45.
49. Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res 2012; 46: 540-8.
50. Stahl SM,. Neuropharmacology of obesity: my receptors make me eat. J Clin Psychiatry 1998; 59: 447-8.